Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (83) Arrow Down
Filter Results: (83) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (187)
    • People  (1)
    • News  (50)
    • Research  (83)
    • Events  (3)
    • Multimedia  (8)
  • Faculty Publications  (52)

Show Results For

  • All HBS Web  (187)
    • People  (1)
    • News  (50)
    • Research  (83)
    • Events  (3)
    • Multimedia  (8)
  • Faculty Publications  (52)
← Page 2 of 83 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • February 2016 (Revised September 2017)
  • Case

Neurotrack and the Alzheimer's Puzzle

By: Richard G. Hamermesh, Liz Kind and Carin-Isabel Knoop
Elli Kaplan founded Neurotrack in 2012 with a breakthrough noninvasive cognitive diagnostics test that will detect Alzheimer's disease in its earliest pre-symptomatic stages. While the company has gained great traction in the three years since it was started, with no... View Details
Keywords: Alzheimer's Disease; Diagnostics; Healthcare; Entrepreneurship; Health Disorders; Science-Based Business; Business Model; Medical Devices and Supplies Industry; United States
Citation
Educators
Purchase
Related
Hamermesh, Richard G., Liz Kind, and Carin-Isabel Knoop. "Neurotrack and the Alzheimer's Puzzle." Harvard Business School Case 816-072, February 2016. (Revised September 2017.)
  • August 2024 (Revised August 2024)
  • Background Note

Note on Adherence in Healthcare

By: Regina E. Herzlinger, Zachery Page and Ben Creo
This note provides an overview of adherence in healthcare. It discusses systemwide costs of non-adherence, common barriers to adherence, relevant stakeholders, novel compliance tactics, and the impact on digital therapeutic adoption. It is recommended as a companion to... View Details
Keywords: Health Care and Treatment; Behavior; Health Industry
Citation
Educators
Related
Herzlinger, Regina E., Zachery Page, and Ben Creo. "Note on Adherence in Healthcare." Harvard Business School Background Note 325-025, August 2024. (Revised August 2024.)
  • September 2013
  • Article

Testimonials Do Not Convert Patients from Brand to Generic Medication

By: John Beshears, James J. Choi, David Laibson, Brigitte C. Madrian and Gwendolyn Reynolds

Objectives: To assess whether the addition of a peer testimonial to an informational mailing increases conversion rates from brand name prescription medications to lower-cost therapeutic equivalents, and whether the testimonial's efficacy increases when... View Details

Keywords: Testimonial; Peer Information; Social Proximity; Communication; Generic Medication; Familiarity; Marketing Communications; Decision Choices and Conditions; Identity; Health Care and Treatment; Marketing Reference Programs; Power and Influence; Brands and Branding; Health Industry
Citation
Read Now
Related
Beshears, John, James J. Choi, David Laibson, Brigitte C. Madrian, and Gwendolyn Reynolds. "Testimonials Do Not Convert Patients from Brand to Generic Medication." American Journal of Managed Care 19, no. 9 (September 2013): e314–e316.
  • October 2012 (Revised March 2022)
  • Case

Kleiner-Perkins and Genentech: When Venture Capital Met Science

By: Felda Hardymon and Tom Nicholas
Genentech is a rare success story in the biotechnology industry. Hundreds of billions of dollars of venture capital have been invested without the expected transformational effects. Established in 1976, Genentech was to develop the new science of recombinant DNA into... View Details
Keywords: Innovation & Entrepreneurship; Venture Capital; Innovation and Invention; Entrepreneurship; Information Technology; Science; Biotechnology Industry; United States
Citation
Educators
Purchase
Related
Hardymon, Felda, and Tom Nicholas. "Kleiner-Perkins and Genentech: When Venture Capital Met Science." Harvard Business School Case 813-102, October 2012. (Revised March 2022.)
  • May 2005 (Revised April 2010)
  • Case

GlaxoSmithKline: Reorganizing Drug Discovery (A)

By: Robert S. Huckman and Eli Strick
Describes the reorganization of drug discovery at GlaxoSmithKline (GSK) following the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization placed nearly 2,000 research scientists into six centers of excellence in drug discovery... View Details
Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Operations; Organizational Structure; Performance Improvement; Research and Development; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Huckman, Robert S., and Eli Strick. "GlaxoSmithKline: Reorganizing Drug Discovery (A)." Harvard Business School Case 605-074, May 2005. (Revised April 2010.)
  • April 2019
  • Case

Barber Cardiosystems

By: Ranjay Gulati and Paul S. Myers
Barber Cardiosystems, based in Melbourne, Australia, designs and manufactures therapeutic devices used for treatment of coronary conditions. Over four decades, it has grown to be among the top 200 medical device companies in the world. It competes against much larger... View Details
Keywords: Organizational Behavior; Strategic Alignment; Cost Management; Performance Productivity; Organizational Culture; Motivation and Incentives; Organizational Design; Strategy; Leadership; Medical Devices and Supplies Industry; Australia
Citation
Educators
Purchase
Related
Gulati, Ranjay, and Paul S. Myers. "Barber Cardiosystems." Harvard Business School Brief Case 919-505, April 2019.
  • November 2024
  • Teaching Note

Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams

By: Debora L. Spar and Julia M. Comeau
Teaching Note for HBS Case No. 323-039. In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At... View Details
Keywords: Pharmaceutical Companies; Technological And Scientific Innovation; Organ Donation; Health Care and Treatment; Health Disorders; Innovation and Invention; Growth and Development Strategy; Product Development; Pharmaceutical Industry; Medical Devices and Supplies Industry; United States; District of Columbia
Citation
Purchase
Related
Spar, Debora L., and Julia M. Comeau. "Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams." Harvard Business School Teaching Note 325-058, November 2024.
  • January 2018
  • Case

Spark Therapeutics: Pioneering Gene Therapy

By: Robert F. Higgins and Tina Liu
Spark Therapeutics is a pioneering gene therapy startup. It was spun out of The Children’s Hospital of Philadelphia (CHOP). The company had taken with it much of the intellectual property and talent that CHOP had developed. The company is considering an initial public... View Details
Keywords: Health Care and Treatment; Innovation and Invention; Business Startups; Opportunities; Problems and Challenges; Strategy
Citation
Educators
Purchase
Related
Higgins, Robert F., and Tina Liu. "Spark Therapeutics: Pioneering Gene Therapy." Harvard Business School Case 818-059, January 2018.
  • February 2010 (Revised April 2010)
  • Case

Organization and Strategy at Millennium (A)

By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark... View Details
Keywords: Transformation; Leading Change; Management Succession; Organizational Change and Adaptation; Competitive Strategy; Competitive Advantage; Biotechnology Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (A)." Harvard Business School Case 710-415, February 2010. (Revised April 2010.)
  • March 17, 2017
  • Article

How Economics Can Shape Precision Medicines

By: Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra
Many public and private efforts in coming years will focus on research in precision medicine, developing biomarkers to indicate which patients are likely to benefit from a certain treatment so that others can be spared the cost—financial and physical—of being treated... View Details
Keywords: Health Care and Treatment; Research; Economics; Motivation and Incentives
Citation
Find at Harvard
Register to Read
Related
Stern, Ariel Dora, Brian M. Alexander, and Amitabh Chandra. "How Economics Can Shape Precision Medicines." Science 355, no. 6330 (March 17, 2017): 1131–1133.
  • February 2010
  • Supplement

Organization and Strategy at Millennium (B)

By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder CEO Mark... View Details
Keywords: Leading Change; Transformation; Decision Choices and Conditions; Crisis Management; Competitive Advantage; Commercialization; Selection and Staffing; Product Development; Organizational Change and Adaptation; Pharmaceutical Industry
Citation
Purchase
Related
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (B)." Harvard Business School Supplement 710-418, February 2010.
  • October 2022
  • Case

Lyra Health: Transforming Mental Health

By: Rembrand Koning and Nicole Keller
In January 2022, Lyra Health was deciding between several different alternatives to grow the business. Founded in 2015, Lyra Health, was a digital mental health platform that combined technology with human therapists and coaches to deliver high quality mental health... View Details
Keywords: Mental Health; Health Care and Treatment; Corporate Entrepreneurship; Customer Value and Value Chain; Growth and Development Strategy; Expansion; Health Industry; Technology Industry; San Francisco
Citation
Educators
Related
Koning, Rembrand, and Nicole Keller. "Lyra Health: Transforming Mental Health." Harvard Business School Case 723-365, October 2022.
  • January 2020
  • Case

Celata Bioinnovations

By: John R. Wells and Benjamin Weinstock
In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process.... View Details
Keywords: Drug Development; Drug Discovery; Drug Trials; Pharmaceutical Companies; Pharmaceutical Company; Pharmaceuticals; Therapeutics; Biologics; Biotech; Biotechnology; Biopharmacy Company; Biochemistry; Technology Commercialization; Technology Companies; Drug Testing; Startup; Start-up; Startups; Start-ups; Startup Financing; Strategic Decision Making; Strategic Decisions; Strategic Evolution; FDA; Food And Drug Administration; Clinical Trials; Disease Management; Market Attractiveness; Market Entry; Market Opportunities; Health Disorders; Technological Innovation; Information Technology; Commercialization; Business Startups; Finance; Decision Making; Strategy; Market Entry and Exit; Opportunities; Pharmaceutical Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Wells, John R., and Benjamin Weinstock. "Celata Bioinnovations." Harvard Business School Case 720-427, January 2020.
  • 26 Jul 2016
  • Working Paper Summaries

The Impact of the Entry of Biosimilars: Evidence from Europe

Keywords: by Fiona Scott Morton, Ariel Dora Stern, and Scott Stern; Health; Biotechnology; Pharmaceutical
  • March 2010 (Revised May 2012)
  • Case

Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration

By: Karim R. Lakhani and Paul R. Carlile
This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for... View Details
Keywords: Research and Development; Intellectual Property; Risk and Uncertainty; Strategic Planning; Collaborative Innovation and Invention; Health Disorders; Pharmaceutical Industry; Biotechnology Industry; Health Industry
Citation
Educators
Purchase
Related
Lakhani, Karim R., and Paul R. Carlile. "Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration." Harvard Business School Case 610-074, March 2010. (Revised May 2012.)
  • November 2012 (Revised January 2013)
  • Case

Companion Diagnostics: Uncertainties for Approval and Reimbursement

By: Richard G. Hamermesh, Norman C. Selby and Phillip Andrews
The FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine. The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory... View Details
Keywords: Models Of Reimbursement; Personalized Medicine; Regulation; Healthcare Reform; Health Care and Treatment; Health Industry; United States
Citation
Educators
Purchase
Related
Hamermesh, Richard G., Norman C. Selby, and Phillip Andrews. "Companion Diagnostics: Uncertainties for Approval and Reimbursement." Harvard Business School Case 813-037, November 2012. (Revised January 2013.)
  • Article

Affording to Wait: Medicare Initiation and the Use of Health Care

By: Guy David, Philip Saynisch, Victoria Acevado-Perez and Mark D. Neuman
Delays in receipt of necessary diagnostic and therapeutic medical procedures related to the timing of Medicare initiation at age 65 years have potentially broad welfare implications. We use 2005–2007 data from Florida and North Carolina to estimate the effect of... View Details
Keywords: Medicare; Behavior; Insurance; Health Care and Treatment; Insurance Industry; Public Administration Industry; Health Industry; North Carolina; Florida
Citation
Find at Harvard
Purchase
Related
David, Guy, Philip Saynisch, Victoria Acevado-Perez, and Mark D. Neuman. "Affording to Wait: Medicare Initiation and the Use of Health Care." Health Economics 21, no. 8 (August 2012): 1030–1036.
  • July 2023 (Revised July 2024)
  • Case

Miracle Therapeutics: Negotiating an IP License (A)

By: Satish Tadikonda, Michael Singer, William Marks and Wendi Yajnik
(General Experience Case) Beth Sharp and Jennifer Brilliant founded Miracle Therapeutics based on intellectual property developed by Brilliant and her post-doctoral student, John Supreme, in Brilliant’s lab at Elite University (EU). Miracle will have to obtain a... View Details
Keywords: Business Startups; Entrepreneurship; Patents; Negotiation Process
Citation
Educators
Purchase
Related
Tadikonda, Satish, Michael Singer, William Marks, and Wendi Yajnik. "Miracle Therapeutics: Negotiating an IP License (A)." Harvard Business School Case 824-020, July 2023. (Revised July 2024.)
  • September 2022
  • Article

Find and Replace: R&D Investment Following the Erosion of Existing Products

By: Joshua L. Krieger, Xuelin Li and Richard T. Thakor
How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using FDA Public Health Advisories as idiosyncratic negative shocks to approved drugs, we first... View Details
Keywords: R&D Investments; Drug Development; Product Shocks; M&A; Biopharmaceutical Industry; FDA; System Shocks; Research and Development; Investment; Decision Making; Pharmaceutical Industry
Citation
SSRN
Find at Harvard
Read Now
Related
Krieger, Joshua L., Xuelin Li, and Richard T. Thakor. "Find and Replace: R&D Investment Following the Erosion of Existing Products." Management Science 68, no. 9 (September 2022): 6552–6571.
  • September 2020
  • Case

Minerva 2004: Discovery

By: John R. Wells and Benjamin Weinstock
After nearly five years in operation, Doctor Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), was reflecting on the company’s next steps. In a few short years, she and her small team had managed to develop a nanoparticle process for... View Details
Keywords: Entrepreneurship; Financing and Loans; Strategy; Decision Choices and Conditions; Biotechnology Industry
Citation
Educators
Purchase
Related
Wells, John R., and Benjamin Weinstock. "Minerva 2004: Discovery." Harvard Business School Case 721-389, September 2020.
  • ←
  • 1
  • 2
  • 3
  • 4
  • 5
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.